|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Interactions Between Anandamide and Corticotropin-Releasing Factor Signaling Modulate Human Amygdala Function and Risk for Anxiety Disorders: An Imaging Genetics Strategy for Modeling Molecular Interactions.
|
26923505 |
2016 |
|
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Because CRF expression in the central nucleus of the amygdala (CeA) is a key modulator in adaptation to chronic stress, and central administration of CRF inhibits the hypothalamic GnRH pulse generator, we tested the hypothesis that overexpression of CRF in the CeA of female rats alters anxiety behavior, dysregulates the HPA axis response to stress, changes pubertal timing, and disrupts reproduction.
|
25051447 |
2014 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The corticotropin releasing hormone (CRH) system has been implicated in a variety of anxiety and mood-based symptoms and disorders.
|
24123648 |
2013 |
|
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
However, reductions in anxiety and corticosteroid levels conferred by heterozygosity of CRF receptor type-1 do not improve a deficit in working memory observed in APP/hAβ/PS1 mice, suggesting that perturbations of the CRF system are not the primary cause of decreased cognitive performance.
|
22336193 |
2012 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
In addition, elevated CRF in cerebrospinal fluid is observed in mood and anxiety disorder patients, suggesting that CRF is also being overproduced from extrahypothalamic sources such as the central amygdala (CeA) and overactivity of the amygdala in neuroimaging studies is a consistent finding in anxiety and depression patients.
|
21616602 |
2012 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
Crh and Oprm1 mediate anxiety-related behavior and social approach in a mouse model of MECP2 duplication syndrome.
|
22231481 |
2012 |
|
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Corticotropin-releasing factor (CRF) has a key role in the central stress response, and altered levels of this neuropeptide are linked to stress-related psychopathologies such as anxiety and depression.
|
20548294 |
2011 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
A concatenation of findings from preclinical and clinical studies support a preeminent function for the corticotropin-releasing factor (CRF) system in mediating the physiological response to external stressors and in the pathophysiology of anxiety and depression.
|
20010888 |
2010 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
DHEA-S injection had no effect on anxiety level in passive rats that typically demonstrate high level of trait-anxiety and resistance to CRH.
|
21268831 |
2010 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
The corticotropin-releasing factor (CRF, or corticotropin-releasing hormone) and arginine vasopressin systems have been implicated in the pathophysiology of anxiety and depressive disorders and response to antidepressant treatment.
|
20368512 |
2010 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
CRF receptor 1 regulates anxiety behavior via sensitization of 5-HT2 receptor signaling.
|
20383137 |
2010 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
Restraint-induced corticosterone secretion and hypothalamic CRH mRNA expression are augmented during acute withdrawal from chronic cocaine administration.
|
17293045 |
2007 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Corticotropin-releasing factor, vasopressin and receptor systems in depression and anxiety.
|
16733617 |
2006 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
CRF also increased anxiety/fear-like behaviors in the forced swim and predator odor tests.
|
16495007 |
2006 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Corticotropin-releasing hormone (CRH) has been implicated in the pathophysiology of anxiety disorders and depression.
|
16884458 |
2006 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Genetic modifications of the CRH system by conventional and conditional gene targeting strategies in the mouse allowed us to study the endogenous mechanisms underlying HPA system regulation and CRH-related neuronal circuitries involved in pathways mediating anxiety and stress-related behaviour.
|
15771006 |
2005 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Given the fundamental role of the corticotropin-releasing hormone (CRH) system in anxiety, stress-associated pathologies, and mood disorders, we describe genetic modifications of the genes that encode proteins integral to the CRH/CRH receptor system with particular emphasis on conditional gene-targeting strategies.
|
14755129 |
2004 |
|
Anxiety Disorders
|
0.400 |
GeneticVariation
|
group |
BEFREE |
A large body of preclinical and clinical evidence points to a key role of the corticotropin-releasing hormone (CRH) receptor 1 subtype (CRHR1) in mediating CRH-elicited effects in anxiety, depressive disorders and stress-associated pathologies.
|
15310462 |
2004 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Two subtypes of the corticotropin-releasing factor (CRF) receptor, CRF(1) and CRF(2), differentially modulate brain functions such as anxiety and memory.
|
15192151 |
2004 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
BEFREE |
Because both cortisol and CRH have behavioral effects, and hypothalamic CRH hypersecretion has been associated with chronic states of anxiety and depression, we performed endocrine and psychologic studies in consecutively admitted parents of patients with classic congenital adrenal hyperplasia due to 21-OH deficiency and parents of children with other chronic endocrine disorders.
|
15126546 |
2004 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
Taken with the evidence for hypersecretion of CRF in patients with depression and anxiety-related disorders, our findings lead to the intriguing hypothesis that interaction between CRF and 5-HT, especially in the ventral hippocampus, plays a role in the etiology of affective and anxiety disorders.
|
14575894 |
2003 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
Quantifying fear potentiated startle using absolute versus proportional increase scoring methods: implications for the neurocircuitry of fear and anxiety.
|
12424556 |
2002 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
These results suggest that the onset of r/hCRF and rUcn actions related to behavioral responses to anxiety is likely to depend on brain peptide-specific mechanisms including binding properties to CRF-receptors, differential distribution to specific functional brain sites and the distribution and effectiveness of binding-protein interactions.
|
11875628 |
2002 |
|
Anxiety Disorders
|
0.400 |
AlteredExpression
|
group |
BEFREE |
Levels of corticotropin-releasing hormone are elevated in patients with depression and anxiety and are expected to be elevated in patients with congenital adrenal hyperplasia; it is unknown whether patients with 21-hydroxylase deficiency have an increased incidence of these psychiatric disorders.
|
11848730 |
2002 |
|
Anxiety Disorders
|
0.400 |
Biomarker
|
group |
CTD_human |
CRF elicited a wide range of behaviors, which fell into three broad categories: anxiety-like, depressive-like, and externally oriented.
|
12438692 |
2002 |